Clinical Trial Update: The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating lipid reprogramming with rosuvastatin in castrated Egyptian patients with metastatic prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer Metastatic

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: National Cancer Institute, Egypt | Conditions: Prostate Cancer Metastatic | Phase 4 | Status: COMPLETED